In the management of non-Hodgkin lymphoma (NHL), multiple mechanisms of therapy have been developed. These therapies include anti-CD20 antibodies and chimeric antigen receptor T-cell (CAR-T) therapies. With continued developments in NHL management, bispecific antibodies are a promising strategy for use in the relapsed/refractory setting with promising data showing potential for improving outcomes in patient care.
Hide..Show more..
Screenshots
User Rating
0 out of 5
0 ratings
in Ecuador
Ratings History
Reviews
App doesn't have any reviews yet
Store Rankings
Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet
Keywords
Revenue and Downloads
Gain valuable insights into Updates in NHL Management performance with our analytics. Sign up now
to
access downloads, revenue, and more.